Opinion|Videos|September 17, 2024
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
- What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?
Advertisement
Related to this article
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5